BioNTech looks to the future as WHO declares COVID-19 emergency over

The World Health Organization’s (WHO) declaration on Friday that the COVID-19 global emergency status has ended, and that the virus should now be managed alongside other infectious diseases, formally brings to an end what has been an uncertain and difficult time for much of the world.

But for BioNTech (Nasdaq: BNTX), a German company with no previous on-market products that suddenly found itself bringing in billions from sales of Comirnaty, a vaccine for COVID-19 sold in partnership with Pfizer (NYSE: PFE), the announcement, which means that the virus should now be managed along with other infectious diseases, underlined the need to seek growth opportunities elsewhere.

"For the remainder of 2023, we are focused on advancing our disruptive platforms against solid tumors and accelerating clinical programs in infectious diseases of high global need"This fact was likely already obvious on looking at BioNTech’s first-quarter financial results, which were presented on Monday.